I-Mab

Company Profile

I-Mab had its IPO on 2020-01-17 under the ticker symbol IMAB.

The company operates in the Healthcare sector and Biotechnology industry. I-Mab has a staff strength of 0 employees.

Stock update

Shares of I-Mab opened at $1.53 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.5 - $1.65, and closed at $1.59.

This is a +3.92% increase from the previous day's closing price.

A total volume of 1,094,381 shares were traded at the close of the day’s session.

In the last one week, shares of I-Mab have slipped by -18.04%.

I-Mab's Key Ratios

I-Mab has a market cap of $160.29 million, indicating a price to book ratio of 0.5874 and a price to sales ratio of 2.5452.

In the last 12-months I-Mab’s revenue was $-253766000 with a gross profit of $41.59 million and an EBITDA of $-1859417984. The EBITDA ratio measures I-Mab's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, I-Mab’s operating margin was 679.87% while its return on assets stood at -25.36% with a return of equity of -66.16%.

In Q1, I-Mab’s quarterly earnings growth was a positive 0% while revenue growth was a negative 62.1%.

I-Mab’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-3.6 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into I-Mab’s profitability.

I-Mab stock is trading at a EV to sales ratio of 0.4386 and a EV to EBITDA ratio of 0.1013. Its price to sales ratio in the trailing 12-months stood at 2.5452.

I-Mab stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$3.51 billion

Total Liabilities

$663.07 million

Operating Cash Flow

$0

Capital Expenditure

$37.96 million

Dividend Payout Ratio

0%

I-Mab ended 2024 with $3.51 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $3.51 billion while shareholder equity stood at $2.45 billion.

I-Mab ended 2024 with $0 in deferred long-term liabilities, $663.07 million in other current liabilities, 133000.00 in common stock, $-7634946000.00 in retained earnings and $162.57 million in goodwill. Its cash balance stood at $2.36 billion and cash and short-term investments were $2.95 billion. The company’s total short-term debt was $57,292,000 while long-term debt stood at $0.

I-Mab’s total current assets stands at $3.07 billion while long-term investments were $11.41 million and short-term investments were $585.91 million. Its net receivables were $102.35 million compared to accounts payable of $0 and inventory worth $0.

In 2024, I-Mab's operating cash flow was $0 while its capital expenditure stood at $37.96 million.

Comparatively, I-Mab paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.59

52-Week High

$7.67

52-Week Low

$1.5

Analyst Target Price

$28.85

I-Mab stock is currently trading at $1.59 per share. It touched a 52-week high of $7.67 and a 52-week low of $7.67. Analysts tracking the stock have a 12-month average target price of $28.85.

Its 50-day moving average was $2.43 and 200-day moving average was $3.58 The short ratio stood at 4.72 indicating a short percent outstanding of 0%.

Around 74.6% of the company’s stock are held by insiders while 5900% are held by institutions.